Open Access Open Access  Restricted Access Subscription Access

Coronavirus Spike (S) Glycoprotein (2019-Ncov) Targeted Siddha Medicines Kabasura Kudineer and Thonthasura Kudineer–In silico Evidence for Corona Viral Drug


Affiliations
1 State Licensing Authority, Directorate of Indian Medicine (Government of Tamilnadu), Arumbakkam, Chennai − 600106, India
2 Sanjeev Biomedical Research Centre, 1/15, Kumaran Street, Keelkatalai, Chennai − 600117, Tamilnadu, India
 

COVID19 is the prime threat to the human race now. Currently the world faces Covid-19 out-break across all continents and it is characterized by its membrane proteins due to mutations. Siddha Medicine is one of the oldest medical system in the world which is believed to be originated more than 10,000 years ago which is prevalent in the ancient Tamil land. Siddha medicine classifies disease and disorders into 4448 types and has remedy for more than 64 types of fever. Among these Kabasura Kudineer and Thonthasura Kudineer are two siddha formulations used against fevers due to respiratory infections. The present study was carried out to evaluate these two formulations against COVID 19 using in silico docking methods. For that the active principles/phytocompounds from the ingredients of the formulations were docked against coronavirus spike glycoprotein trimmer (PDB ID: 3JCL) using iGEMDOCK software. 10 phytocompounds showed promising activity against COVID spike glycoprotein. This study showed that 10 phytocompounds which act as ligands to bind with viral proteins to prevent the binding of host receptors. Of these Cucurbitacin B (-112.09), Cardiofoliolide (-111.5), Apigenin (-98.84) and Pyrethrin (-92.98) were observed as more effective with less bind energies required for binding with spike proteins to prevent the fusion lead viral replication. Since Kabasura Kudineer contains more active phyto constituents, the higher activity was observed than Thontha sura Kudineer. The study demonstrated that Kabasura Kudineer could be a potential siddha medicine for COVID 19 provided further preclinical and clinical confirmatory studies

Keywords

COVID19, Kabasura Kudineer, Siddha Medicines, Thonthasura Kudineer.
User
Notifications
Font Size

  • Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: A review of virus-host interactions. Diseases. 2016 Jul 25; 4(3):26. https://doi.org/10.3390/diseases4030026. PMid: 28933406, PMCid: PMC5456285.
  • Li W, Wong SK, Li F, Kuhn JH, Huang IC, Choe H, Farzan M. Animal origins of the severe acute respiratory syndrome coronavirus: Insight from ACE2-S-protein interactions. J. Virol. 2006 May; 80(9):4211-19. https://www.ncbi.nlm.nih.gov/pubmed/16611880.
  • Maule GG. Investigation of Host Factors Required for Lymphocytic Choriomening it is Virus Entry. Master of Science Thesis: University of Ottawa; 2019. http://hdl.handle.net/10393/39145.
  • Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bail Q, Bashir N, Xue M. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic 2 options. J Clin Microbiol. 2020 Mar 11; In press. doi:10.1128/ JCM.00187-20. https://doi.org/10.1128/JCM.00187-20. PMid:32161092.
  • Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Bi Y. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet. 2020; 395(10224):565-69. https://doi.org/10.1016/ S0140-6736(20)30255-5.
  • Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Agha R. World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19). Int. J. Surg. 2020; 26(76):71-76. https://doi.org/10.1016/j.ijsu.2020.02.034. PMid: 32112977, PMCid: PMC7105032.
  • Otvos RA, Still KB, Somsen GW, Smit AB, Kool J. Drug discovery on natural products: from ion channels to nAChRs, from nature to libraries, from analytics to assays. SLAS. 2019; 24(3):362-85. https://doi.org/10.1177/2472555218822098. PMid: 30682257, PMCid: PMC6484542.
  • Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li M. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta. Pharmaceutica Sinica B. 2020 Feb 27; In press. https://doi.org/10.1016/j.apsb.2020.02.008.
  • Jain J, Kumar A, Narayanan V, Ramaswamy RS, Sathiyarajeswaran P, Devi MS Sunil S. Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation. J. Ayurveda Integr. Med. Jan 23 2019; doi: 10.1016/j.jaim.2018.05.006. https://www.ncbi.nlm.nih.gov/pubmed/30685096.
  • Anitha John R. Sasikala E, Sathiyarajeswaran. Analysis of kabasurakudineer chooranam-a siddha formulation. Inter. Ayur. Med. J. 2016; 3(9):2915-20. https://www.academia.edu/27020852/ANALYSIS_OF_KABASURAKUDINEER_CHOORANAM-A_SIDDHA_FORMULA-_TION
  • Walls A, Tortorici M, Bosch B. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature. 2016; 531:114-17. https://doi.org/10.1038/nature16988. PMid: 26855426, PMCid: PMC5018210.
  • Krungkrai J, Krungkrai, SR. Antimalarial qinghaosu/ artemisinin: The therapy worthy of a Nobel Prize. Asian Pacific J. Trop. Biomed. 2016; 6(5):371-75. https://doi.org/10.1016/j.apjtb.2016.03.010.

Abstract Views: 1

PDF Views: 1




  • Coronavirus Spike (S) Glycoprotein (2019-Ncov) Targeted Siddha Medicines Kabasura Kudineer and Thonthasura Kudineer–In silico Evidence for Corona Viral Drug

Abstract Views: 1  |  PDF Views: 1

Authors

M. Pitchiah Kumar
State Licensing Authority, Directorate of Indian Medicine (Government of Tamilnadu), Arumbakkam, Chennai − 600106, India
K. Meenakshi Sundaram
Sanjeev Biomedical Research Centre, 1/15, Kumaran Street, Keelkatalai, Chennai − 600117, Tamilnadu, India
M. S. Ramasamy
Sanjeev Biomedical Research Centre, 1/15, Kumaran Street, Keelkatalai, Chennai − 600117, Tamilnadu, India

Abstract


COVID19 is the prime threat to the human race now. Currently the world faces Covid-19 out-break across all continents and it is characterized by its membrane proteins due to mutations. Siddha Medicine is one of the oldest medical system in the world which is believed to be originated more than 10,000 years ago which is prevalent in the ancient Tamil land. Siddha medicine classifies disease and disorders into 4448 types and has remedy for more than 64 types of fever. Among these Kabasura Kudineer and Thonthasura Kudineer are two siddha formulations used against fevers due to respiratory infections. The present study was carried out to evaluate these two formulations against COVID 19 using in silico docking methods. For that the active principles/phytocompounds from the ingredients of the formulations were docked against coronavirus spike glycoprotein trimmer (PDB ID: 3JCL) using iGEMDOCK software. 10 phytocompounds showed promising activity against COVID spike glycoprotein. This study showed that 10 phytocompounds which act as ligands to bind with viral proteins to prevent the binding of host receptors. Of these Cucurbitacin B (-112.09), Cardiofoliolide (-111.5), Apigenin (-98.84) and Pyrethrin (-92.98) were observed as more effective with less bind energies required for binding with spike proteins to prevent the fusion lead viral replication. Since Kabasura Kudineer contains more active phyto constituents, the higher activity was observed than Thontha sura Kudineer. The study demonstrated that Kabasura Kudineer could be a potential siddha medicine for COVID 19 provided further preclinical and clinical confirmatory studies

Keywords


COVID19, Kabasura Kudineer, Siddha Medicines, Thonthasura Kudineer.

References





DOI: https://doi.org/10.18311/ajprhc%2F2020%2F25103